MDMA o éxtasis: Aspectos farmacológicos, toxicológicos y clínicos

Medicina Clinica

Volumn 107, Issue 14, 1996, Pages 549-555

  Prada, Carlos ^a   Álvarez, F Javier ^a,b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT;

DRUG ABUSE; HUMAN; NEUROTOXICITY; NONHUMAN; REVIEW; ADDICTION; ANIMAL; CHEMISTRY;

ANIMALS; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SUBSTANCE-RELATED DISORDERS;

EID: 0030603277     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Shulgin AT, Nichols DE. Characterization of three new psychotomimetics. En: Stillman R, Willette R, editores. The psycopharmacology of hallucinogens. Nueva York: Pergamon Press, 1978; 74-83.
2. Hardman HF, Haavik CO, Seevers MH. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxic Appl Pharmacol 1973; 25: 299-309.
3. Ricaurte GA, Bryan G, Strauss L, Seiden L, Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229: 986-988.
4. Grob CS, Bravo GL, Walsh RN, Liester MB. The MDMA-neurotoxicity controversy: implications for clinical research with novel psychoactive drugs. J Nerv Ment Dis 1992; 180; 355-356.
5. Liester MB, Grob CS, Bravo GL, Walsh RN. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 1992; 180: 345-352.
6. Ministerio de Justicia e Interior, Delegación del Gobierno para el Plan Nacional sobre Drogas. Plan Nacional Sobre Drogas: Memoria 93. Madrid, 1994.
7. Del Rio MC, Gomollón A, Álvarez FJ. Los estudiantes universitarios de Valladolid ante las drogas. Valladolid: Secretariado de Publicaciones, 1994.
8. Camí J. Sintesis clandestina de drogas: pasado, presente y futuro. Med Clin (Barc) 1990; 95: 344-347.
9. García S, Geijo S, Álvarez FJ. Drogas de Diseño. Medicina Integral 1993; 21: 300-309.
10. Prat A, Montero M, Reig P, Sanz P. MDMA (éxtasis): droga de actualidad en España. Rev Clin Esp 1991; 188: 106-108.
11. Elverdin C, Pérez MP. Anfetaminas de Anillo Sustituido. Panorama Actual del Medicamento (PAMGEB) 1992; 154: 278-280.
12. Johnson MP, Hoffman AH, Nichols DE. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]-serotonin and [3H]-dopamine release from superfused rat brain slices. Eur J Pharmacol 1986; 132: 269-276.
13. Berger UV, Xi GF, Azmitia EC. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytriptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 1992; 215: 153-160.
14. Rudnick G, Wall SC. The mollecular mechanism of «ecstasy» [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 1992; 89: 1.817-1.821.
15. Lyon RA, Glennon RA, Titeler M. 3,4-metylenedioxymethamphetamine (MDMA): Steroeselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 1986; 88: 525-526.
16. 2, receptor as a size of action for LSD and central phenylisopropylamine hallucinogens. Psychopharmacology 1988; 94: 213-216.
17. Pan HS, Wang RY. The action of (±)-MDMA on medial prefrontal cortical neurons is mediated through the serotonergic system. Brain Res 1991; 543: 56-60.
18. Yamamoto BK, Spanos LJ. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 1988; 148: 195-203.
19. Nash JF, Brodkin J. Microdialysis Studies on 3,4-Methylenedioxymethamphetamine induced Dopamine Release: Effect of Dopamine Uptake Inhibitors. J Pharmacol Exp Ther 1991; 259: 820-825.
20. Stone DM, Johnson M, Hannson GR, Gibb JW. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 1988; 247: 79-87.
21. Schmidt CJ, Black CK, Taylor VL. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur J Pharmacol 1990; 181: 59-70.
22. Nash JF. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 1990; 47: 2.401-2.408.
23. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: Reversal by L-DOPA. J Pharmacol Exp Ther 1991; 256: 230-235.
24. Johnson M, Bush LG, Hanson GR, Gibb JW. Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striafal neurotensin and dynorphin A concentrations. Biochem Pharmacol 1993; 46: 770-772.
25. Gold LH, Koob GF, Geyer MA. Stimulant and hallucinogenic profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 1988; 247: 547-555.
26. Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. J Psychoactive Drugs 1986; 18: 305-313.
27. a ed.). Madrid: Alianza Editorial, 1992.
28. Greer B, Tolbert P. Subjetive reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986; 18: 319-327.
29. McCann UD, Ricaurte GA. Lasting neuropsychiatric sequalae of (±) 3,4-methylenedioxymethamphetamine (MDMA; «Ecstasy») may be separable from its neurotoxic actions: clinical evidence. J Clin Psychopharmacol 1993; 13: 214-217.
30. Randall T. Ecstasy-fueled «rave» parties become dances of death for English youths. JAMA 1992; 268: 1.505-1.506.
31. Torrens M, Camí J. News from Spain (News and Notes). Addiction 1994; 89: 619-620.
32. Henry JA, Jefreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine («ecstasy»). Lancet 1992; 340: 384-387.
33. Solwij N. Ecstasy (3,4-methylenedioxymethamphetamine). Curr Opin Psychiatry 1993; 6: 411-415.
34. Solwij N, Hall W, Lee N. Recreational MDMA use in Sidney: a profile of «Ecstasy» users and their experience with the drug. Br J Addict 1992; 87: 1.161-1.172.
35. Riedlinger FE. The scheduling of MDMA: a pharmacist's perspective. J Psychoactive Drugs 1985; 17: 167-171.
36. Downing J. The psycological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986; 18: 335-340.
37. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988; 1: 273-277.
38. Siegel RK. MDMA: nonmedical use and intoxication. J Psychoactive Drugs 1986; 18: 349-354.
39. Mamounas LA, Mullen CA, O'Hearn E, Moliver ME. Dual serotonergic projections to forebrain in the rat: Morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 1991; 314: 558-586.
40. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, DeSouza EB. 3,4-Methylenedioxymethamphetamine 3,4-methylenedioxyamphetamine destroy serotonin nerve terminals in rat brain: Quantification of neurodegeneration by measurement of [3H]-paroxetine-labelled uptake sites. J Pharmacol Exp Ther 1987; 242: 911-916.
41. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Moliver ME et al. (±) 3,4-methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988; 260: 51-55.
42. Schmidt CJ, Taylor VL. Depression of rat brain tryptofan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 1987; 36: 4.095-4.102.
43. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987; 241: 338-345.
44. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA Serotonergic recovery after (±) 3,4-methylenedioxymethamphetamine injury: Observations in rodents. J Pharmacol Exp Ther 1993; 264: 1.484-1.491.
45. Zaczek R, Battaglia G, Culp S, Appel NM, Contrera JF, DeSouza EB. Effects of repeated fenfluramine administration function in rat brain: Pharmacokinetic, dose response, regional specificity and time course data. J Phamacol Exp Ther 1990; 253: 104-112.
46. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn EG, Wilson MA. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 1990; 600: 640-664.
47. Insel TR, Battaglia G, Johannessen JN, Marra S, DeSouza EB. 3,4-methylenedioxymethamphetamine («Ecstasy») selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 1989; 249: 713-720.
48. Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of (±) 3,4-methylenedioxymethamphetamine on central serotonergic neurons in the primate: neurochemical observations. J Pharmacol Exp Ther 1992; 261: 616-622.
49. Price LH, Ricaurte GA, Krystal JH, Heninger GR. Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine users. Arch Gen Psychiatry 1989; 46: 20-22.
50. Grob C, Bravo L, Walsh R. Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity. Arch Gen Psychiatry 1990; 47: 288.
51. Steele TD, McCann UD, Ricaurte GA. 3,4-methylenedioxymethamphetamine (MDMA, «Ecstasy»): pharmacology and toxicology in animals and humans. Addiction 1994; 89: 539-551.
52. Suárez RV, Riemmersma T. «Ecstasy» and sudden cardiac death. Am J Forensic Medic Pathol; 9: 339-341.
53. Fahal IH, Sallomi DF, Yaqoob M, Bell GM. Acute renal failure after ecstasy. Br Med J 1992; 305: 29.
54. De Silva RN, Harries DP. Misuse of ecstasy. Br Med J 1992; 305: 310.
55. Rothwell PM, Grant R. Cerebral venous sinus thrombosis induced by «ecstasy». J Neurol Neurosurg Psychyatry 1993; 46: 1.035.
56. Ginsberg MD, Hertzman M, Schmidt-Nowara WW. Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. Ann Intern Med 1970; 73: 81-85.
57. Chadwick IS, Linsey A, Freemont AJ, Doran B, Curry PD. Ecstasy, 3,4-methylenedioxymethamphetamine (MDMA), a fatality with coagulopathy and hyperthermia. J R Soc Med 1991; 84: 371.
58. Screaton GR, Cairns HS, Sarner M, Singer M, Thrasher A, Cohen SL. Hyperpyrexia and rhabdomyolisis after MDM («ecstasy») abuse. Lancet 1992; 339: 677-678.
59. Barret PJ, Taylor GT. «Ecstasy» ingestion: a case report of severe complications. J R Soc Med 1993; 86: 223-234.
60. Shearman JD, Chapman RWG, Satsangi J, Ryley NG, Weatherhead S. Misuse of Ecstasy. Br Med J 1992; 305: 309.
61. Winstock AR. Chronic paranoid psychosis after misuse of 3,4-methylenedioxymethamphetamine. Br Med J 1991; 302: 1.150-1.151.
62. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents?. Neuropsychopharmacology 1993; 8: 171-176.
63. Schifano F. Chronic atypical psychosis associated with MDMA («Ecstasy») abuse. Lancet 1991; 338: 1.335.
64. Whitaker-Azmitia PM, Aronson TA. «Ecstasy» (3,4-methylenedioxymethamphetamine) induced panic. Am J Psychiatry 1989; 146: 119.
65. Greer G, Strassman RJ. Information on Ecstasy. Am J Psychiatry 1985; 142: 1.391.
66. McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (± 3,4-methylenedioxymethamphetamine («ecstasy») in recreational users. J Clin Psychopharmacol 1991; 11: 302-305.
67. Krystal JH, Price LH, Opshal C, Ricaurte GA, Heninger GR. Chronic 3,4-methytenedioxymethamphetamine (MDMA) use: effects on mood and neuropsycological function? Am J Drug Alcohol Abuse 1992; 18: 331-341.
68. Henry JA. Ecstasy and the dance of death. Br Med J 1992; 305: 5-6.
69. Stone RJ. Treatment of «ecstasy» overdose with dantrolene. Anaesthesia 1993; 48: 83.